SRSF2 and leukemia: Moreover, small-molecule compounds that target the essential splice factor SF3B, such as spliceostatin A and E710758,59, have shown efficacy in leukemia models harboring mutations in the same or different trans-acting splice factors, namely SF3B1, SRSF2, or U2AF35, which sensitize the cells to the inhibitors60–63, though inhibition of SF3B also evokes global intron retention and cytotoxicity.